70 completed, 25 recruiting, 22 unknown, 15 terminated. 161 Phase 2, 33 Phase 1, 15 Phase 3.
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease IVIG, Aspirin, Firsekibart - Kawasaki Disease | Phase 2 / Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 90 | 2026-11-01 | 2026-10-22 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. Repository Corticotropin Injection (ACTH), Study-matched inactive placebo injection, also called control injection - Behçet's Syndrome, Behçet's Syndrome (BS) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-09-01 | 2026-09-22 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis BBD-1 Multi target Immune Enhancement Targeting Agent - Allergic Reaction (IgA) Vasculitis | Phase 2 | Recruiting | Qifeng Zhang | 30 | 2026-08-10 | 2026-08-11 |
| Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) NM8074, Placebo - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2026-06-01 | 2025-03-11 |
| Bosentan in the Treatment of Giant Cell Arteritis Bosentan, Glucocorticoids - Giant Cell Arteritis (GCA) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 40 | 2026-06-01 | 2026-05-06 |
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel Sesame Oil, Aloe vera gel, Control - Cancer, Chemotherapy | Phase 2 | Not yet recruiting | University of Basrah | 190 | 2026-05-11 | 2026-04-28 |
| Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients Secukinumab, Standard of Care (SOC) - Takayasu Arteritis, Large Vessel Vasculitis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 52 | 2026-04-01 | 2026-03-27 |
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement Baricitinib - Kohlmeier-Degos Disease, Malignant Atrophic Papulosis | Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 12 | 2026-02-18 | 2026-09-18 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis Tocilizumab, Discontinue Tocilizumab - Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 78 | 2026-01-05 | 2026-08-10 |
| Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis Obinutuzumab - Granulomatosis With Polyangiitis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2025-12-19 | 2026-03-06 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Placebo, Tarperprumig - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2025-11-26 | 2026-06-16 |
Showing 20 of 161. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (31) · Granulomatosis with Polyangiitis (30) · Behcet Syndrome (28) · Giant Cell Arteritis (22) · Microscopic Polyangiitis (16) · Mucocutaneous Lymph Node Syndrome (12) · Churg-Strauss Syndrome (11) · Lupus Erythematosus, Systemic (11) · Takayasu Arteritis (9) · Scleroderma, Systemic (8) · Uveitis (8) · Dermatomyositis (7) · Myositis (7) · Arteritis (5)
Vascular Diseases (160) · Cardiovascular Diseases (156) · Skin and Connective Tissue Diseases (140) · Skin Diseases (137) · Skin Diseases, Vascular (134) · Immune System Diseases (100) · Autoimmune Diseases (85) · Systemic Vasculitis (58) · Nervous System Diseases (51) · Brain Diseases (40) · Central Nervous System Diseases (40) · Cerebrovascular Disorders (40) · Hemic and Lymphatic Diseases (37) · Eye Diseases (35)
Cyclophosphamide (14) · Rituximab (14) · Prednisone (13) · tocilizumab (11) · Infliximab (9) · Glucocorticoids (8) · Azathioprine (6) · Methotrexate (6) · Mycophenolic Acid (5) · Abatacept (4) · Etanercept (4) · Interleukin 1 Receptor Antagonist Protein (4) · Methylprednisolone (4) · Prednisolone (4) · baricitinib (4)
Assistance Publique - Hôpitaux de Paris (11) · Cambridge University Hospitals NHS Foundation Trust (9) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Novartis Pharmaceuticals (6) · University of Pennsylvania (5) · Liu Tian (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (4) · Amgen (3) · Insel Gruppe AG, University Hospital Bern (3) · Imperial College London (2) · InflaRx GmbH (2) · Massachusetts General Hospital (2) · NYU Langone Health (2) · Peking Union Medical College Hospital (2)
United States (64) · China (25) · United Kingdom (24) · France (20) · Germany (15) · Canada (14) · Italy (10) · Netherlands (8) · Spain (7) · Turkey (Türkiye) (7) · Australia (6) · Belgium (5) · Poland (5) · Sweden (5) · Switzerland (5)
David Jayne (4) · Peter A. Merkel, MD, MPH (3) · Bahar Sadeghi, MD (2) · Carol A. Langford, MD, MHS (2) · Cornelia D Cudrici, M.D. (2) · Jane C Burns, MD (2) · John H. Stone, MD, MPH (2) · Patrick H Nachman, MD (2) · Ulrich Specks, MD (2) · Wenjie Zheng, M.D. (2) · Adriana H Tremoulet, MD (1) · Ahmet Gul, MD (1)
PMID 33164993, PMID 36853224, PMID 12631091, PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 17470830, PMID 17954800, PMID 18528326, PMID 19425235, PMID 19451574, PMID 19597921, PMID 1970380, PMID 19717547, PMID 19826112, PMID 20622770, PMID 20647199, PMID 20704622, PMID 20926833, PMID 21218740, PMID 21325353, PMID 21471870, PMID 2161532, PMID 21859691, PMID 21873264, PMID 22127969, PMID 22129253, PMID 22147444, PMID 22211087, PMID 22975753, PMID 23372097, PMID 23563998, PMID 23615499, PMID 23653652, PMID 23754238, PMID 23902481, PMID 24033923, PMID 24323392, PMID 24373830, PMID 24574239, PMID 25047592, PMID 25638011, PMID 25776953, PMID 25858045, PMID 25875256, PMID 26312852, PMID 26387933
2018 (2), P01DK058335 (2), U54AR057319 (2), 2014 (1), 2016 (1), 2017 (1), 2019 (1), 2023 (1), 2025 (1), 268200700036C-5-0-1 (1), R01HL034545 (1), UL1RR024150 (1)